SNORD121B: A Potential Drug Target and Biomarker (G101340252)

Target Name: SNORD121B

NCBI ID: G101340252

SNORD121B

Other Name(s): small nucleolar RNA, C/D box 121B | Small nucleolar RNA, C/D box 121B

SNORD121B: A Potential Drug Target and Biomarker

SNORD121B, short for Sodium Channel OverExpression and Recyclization, is a gene that has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. The sodium channels are a critical aspect of the nervous system, as they regulate the flow of electrical impulses. Malfunctioning sodium channels have been implicated in a wide range of neuropsychiatric disorders, including epilepsy, bipolar disorder, and schizophrenia. Therefore, targeting SNORD121B could potentially lead to new treatments for these disorders.

The SNORD121B gene was first identified in 2002 by researchers at the University of California, San Diego. The gene is located on chromosome 12q34 and encodes a protein known as SNORD121B. SNORD121B is a member of the TRPV2 family of voltage-gated sodium channels, which are responsible for mediating the rapid influx of electrical impulses into the nervous system.

Research has shown that SNORD121B is expressed in a variety of tissues and cells, including the brain, heart, and pancreas. It is also highly co-expressed with the voltage-gated sodium channel alpha-2 (Na+/K+ ATPase), which is a critical ion channel involved in the regulation of ion channels and the control of intracellular signaling pathways.

In addition to its expression in neural tissues, SNORD121B has also been shown to be involved in various physiological processes, including cell signaling, DNA replication, and cell survival. It has been shown to play a role in the regulation of ion channels in the brain, including the function of the sodium channels.

Given the potential involvement of SNORD121B in various physiological processes, it has become an attractive target for drug development. Researchers have been exploring the use of various drug molecules, such as small molecules, peptides, and proteins, to modulate the activity of SNORD121B and its downstream targets.

One approach to targeting SNORD121B is to use small molecules that can modulate the activity of sodium channels. Small molecules such as amiloride, a commonly used drug for the treatment of epilepsy, have been shown to inhibit the activity of SNORD121B and its downstream targets. Similarly, peptides that contain specific amino acids that are involved in the regulation of sodium channels have also been shown to be effective in modulating the activity of SNORD121B.

Another approach to targeting SNORD121B is to use proteins that can modulate the activity of sodium channels. One such protein is known as p120, which is a known modulator of the activity of sodium channels. p120 has been shown to interact with SNORD121B and modulate its activity. Researchers have also shown that the addition of p120 to SNORD121B can increase the activity of the sodium channels, suggesting that it may be a useful drug target for the treatment of certain neurological disorders.

In addition to its potential use as a drug target, SNORD121B has also been identified as a potential biomarker for various neurological disorders. The expression of SNORD121B has been shown to be affected by a variety of factors, including disease, pharmacological treatment, and environmental factors. This suggests that SNORD121B could be a useful biomarker for the diagnosis and monitoring of certain neurological disorders.

Targeting SNORD121B as a drug target or biomarker is still in the early stages of research, and more studies are needed to fully understand its potential role in the treatment of neurological disorders. However, the research being done in this field has the potential

Protein Name: Small Nucleolar RNA, C/D Box 121B

The "SNORD121B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD121B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets